| CAS |
960203-27-4 |
| Chinese Name |
氢溴酸沃替西汀 |
| English Name |
Vortioxetine Hydrobromide |
| Synonyms |
Lu AA21004 hydrobromide |
| Molecular Formula |
C18H23BrN2S |
| Molecular Weight |
379.36 |
| Solubility |
Soluble in DMSO(Need ultrasonic) |
| Purity |
≥98% |
| Appearance |
Light yellow to yellow Solid |
| Storage |
Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL |
MFCD00003305 |
| SMILES |
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C.Br |
| InChIKey |
VNGRUFUIHGGOOM-UHFFFAOYSA-N |
| InChI |
InChI=1S/C18H22N2S.BrH/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20;/h3-8，13，19H，9-12H2，1-2H3;1H |
| PubChem CID |
56843850 |
| Target Point |
5-HT Receptor;Serotonin Transporter |
| Passage |
Neuronal Signaling；GPCR & G Protein |
| Background |
It is an inhibitor of the 5-HT1A, 5-HT1B, 5-HT3A, 5-HT7 receptor and the serotonin transporter (SERT). |
| Biological Activity |
Vortioxetine Hydrobromide 是 5-HT1A，5-HT1B，5-HT3A，5-HT7 受体 和5-羟色胺转运体 (SERT) 的抑制剂，其Ki值分别为 15 nM，33 nM，3.7 nM，19 nM 和 1.6 nM。[1] |
| In Vitro |
Vortioxetine hydrobromide is a novel multimodal serotonergic compound，displaying high affinity for recombinant human 5-HT(1A)(K(i)= 15 nM)，5-HT(1B)(K(i)= 33 nM)，5-HT(3A)(K(i)= 3.7 nM)，5-HT(7)(K(i)= 19 nM)，and noradrenergic β(1)(K(i)= 46 nM)receptors，and SERT(K(i)= 1.6 nM). [1] |
| In Vivo |
In conscious rats，Vortioxetine hydrobromide significantly increased extracellular 5-HT levels in the brain after acute and 3 days of treatment. Following the 3-day treatment(5 or 10(mg/kg)/day)SERT occupancies were only 43% and 57%，respectively. [1]Acute and repeated dosing of vortioxetine(5 or 10(mg/kg)/day)produced more pronounced anxiolytic- and antidepressant-like activities than fluoxetine.[2]Vortioxetine(10mg/day)did not impair driving，cognitive，or psychomotor performance after single or multiple doses.[3]Vortioxetine 5mg did not improve symptoms of generalized anxiety disorder(GAD; HAM-A total score ≥20 and MADRS score ≤16) over 8 weeks of treatment.[4]Vortioxetine has antidepressant- and anxiolytic-like effects in the rat forced swim(Flinders Sensitive Line)and social interaction and conditioned fear tests(minimal effective doses: 7.8，2.0，and 3.9 mg/kg). [5] |
| Animal Experiment |
Vortioxetine was assessed in BalB/cJ@RJ mice using the open-field and forced-swim tests(acute: p.o. 1 h，repeated: daily p.o. 21 days)，and in 129S6/SvEvTac mice using the novelty suppressed feeding paradigm(acute: p.o. 1 h，sustained: daily p.o. 14 or 21 days). Fluoxetine and diazepam were controls. [2] |
| Data Literature Source |
[1]. Bang-Andersen B，et al. Discovery of 1-[2-(2，4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21.
[2]. Guilloux JP，et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology. 2013 Oct;73:147-59.
[3]. Theunissen EL，et al. A randomized trial on the acute and steady-state effects of a new antidepressant，vortioxetine (Lu AA21004)，on actual driving and cognition. Clin Pharmacol Ther. 2013 Jun;93(6):493-501.
[4]. Rothschild AJ，et al. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized，double-blind，placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol. 2012 Dec;22(12):858-66.
[5]. M rk A，et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012 Mar;340(3):666-75. |
| Unit |
Bottle |
| Specification |
10mg |
English
中文
Manual Download
